Figures & data
Figure 1 Respimat® Soft Mist Inhaler™. Reprinted from CitationDalby R, Spallek M, Voshaar T. 2004. A review of the development of Respimat® Soft Mist Inhaler™. Int J Pharm, 283:1–9. Copyright © 2004, with permission from Elsevier.
Figure 2 Schematic of Respimat® Soft Mist Inhaler™ showing the details of the uniblock. Reprinted from CitationDalby R, Spallek M, Voshaar T. 2004. A review of the development of Respimat® Soft Mist Inhaler™. Int J Pharm, 283:1–9. Copyright © 2004, with permission from Elsevier.
Figure 3 (a) Mean aerosol spray velocities at 10 cm from nozzle for Respimat® and various CFC- and HFA-pMDIs. (b) Mean spray duration for the devices. Reprinted from CitationHochrainer D, Hölz H, Kreher C, et al. 2005. Comparison of the aerosol velocity and spray duration of Respimat® Soft Mist Inhaler™ and pressurized metered dose inhalers. J Aerosol Med, 18:273–82. Copyright © 2005, with permission from Mary Ann Liebert, Inc.
Table 1 Mean percentage dose of steroid deposited (and range) for different devices in asthmatic subjects (modified from CitationPitcairn et al 2005)
Figure 4 Typical scintigraphic images for Respimat®, Turbuhaler® DPI at slow and fast inhaled flow rates, and CFC-pMDI. Reprinted from CitationPitcairn G, Reader S, Pavia D, et al. 2005. Deposition of corticosteroid aerosol in the human lung by Respimat® Soft Mist™ Inhaler compared with deposition by metered dose inhaler or by Turbuhaler® dry powder inhaler. J Aerosol Med, 18:264–72. Copyright © 2005, with permission from Mary Ann Liebert, Inc.
Figure 5 Change in FEV1 from pre-dose value in first 60 minutes after dosing on day 85 for IB/FEN delivered by Respimat® (two doses) and by pMDI compared with placebo devices in COPD patients. Reprinted from CitationKilfeather SA, Ponitz HH, Beck E, et al. 2004. Improved delivery of ipratropium bromide/fenoterol from Respimat® Soft Mist™ Inhaler in patients with COPD. Respir Med, 98:387–97. Copyright © 2004, with permission from Elsevier.
